RxDoctor Payments Data

Beth Loessin

Family · Columbus, OHNPI 1013519404

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,213 of the $33,552 with a category attached, or 63.2%. Medtronic accounts for 77.0% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $16,008, more than ten times the $127 reported in 2021. Among family clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,552in general payments, 2019–2025

Across 180 payments — averaging $186.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$26K
  • Boston Scientific$7K
  • Abbott$317
  • Biosense Webster, Inc.$293
  • Johnson & Johnson$142
  • Pfizer$108
  • plus $197 from 4 others

What the payments were for

  • Speaking & faculty fees$21,21363%
  • Travel & lodging$6,27419%
  • Food & beverage$6,01218%
  • Education$520%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,552 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$32,255
Medicare patients
276
Services billed
302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban251$186,739
XareltoRivaroxaban90$65,664
Flecainide Acetate45$1,931
Metoprolol Succinate94$811
Amiodarone Hcl53$809
Diltiazem 24hr Er (Cd)Diltiazem Hcl21$185
Metoprolol Tartrate35$131
Pantoprazole Sodium12$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$108$186,739251 claims
Johnson & JohnsonXarelto$142$65,66490 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →